Sleep drug YZJ-1139 put to the test in kidney patients

NCT ID NCT06671444

Completed Knowledge-focused Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study examines how the sleep aid YZJ-1139 behaves in people with severe kidney impairment compared to those with normal kidney function. Sixteen adults will receive a single 20 mg dose, and researchers will measure drug levels in the blood and urine, as well as any side effects. The goal is to understand if kidney problems change how the drug is processed, which could lead to safer dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YZJ-1139
What this could lead to: If successful, this study could provide dosing guidance for using YZJ-1139 in people with kidney disease, making the drug safer for this group.
What could go wrong: This is a very early, small study (16 people) focused on drug levels, not on treating insomnia. Results may not apply to all kidney patients or predict real-world effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease impaired renal function disease insomnia kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA RENAL IMPAIRMENT

Contacts and locations

Locations

The First Affiliated Hospital of Bengbu Medical University

Bengbu, China
The First Affiliated Hospital of Xuzhou Medical University

Xuzhou, China
Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.